Pandanus fascicularis as a Potential Anticancer Agent: A Review

Read full text Summarise with VIRAT
Authors: Minakshi Khairnar*, Khushi Bhadane, Sanket Gharte, Varsharani Pawar, Aakanksha Dashpute, Dr. Ganesh Ahire
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cancer is a leading cause of mortality worldwide, characterized by uncontrolled cell proliferation, resistance to apoptosis, and metastasis. Limitations of conventional therapies, including toxicity and drug resistance, highlight the need for safer and more effective alternatives. Medicinal plants have gained attention as potential sources of anticancer agents due to their diverse bioactive compounds and multi-targeted mechanisms. Pandanus fascicularis Lam., a member of the Pandanaceae family, is traditionally used for various therapeutic purposes and exhibits significant pharmacological activities. This review focuses on the anticancer potential of Pandanus fascicularis, emphasizing its phytochemical composition and underlying mechanisms. The plant contains flavonoids, phenolics, alkaloids, terpenoids, tannins, and saponins, which contribute to its antioxidant and anti-inflammatory properties. These compounds help in scavenging reactive oxygen species, reducing oxidative stress, and inhibiting inflammation-associated carcinogenesis. Additionally, Pandanus fascicularis demonstrates cytotoxic and antiproliferative effects, induces apoptosis via caspase activation, and causes cell cycle arrest by regulating cyclins and cyclin-dependent kinases. Furthermore, it modulates key molecular pathways such as NF-κB, PI3K/Akt, and MAPK, thereby inhibiting tumor growth and progression. Although promising, further experimental and clinical studies are required to validate its efficacy and safety.

Fields of Study & Subjects

Medicinal Plant Research Phytochemical Studies and Bioactivities Bioactive natural compounds

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 March 2026
Language
EN